protective immunity make human mAb an ideal reagent to examine the mechanism of protection against Pf in man.
For this reason, we have used recent advances in the production of human mAb by the hydridoma technique (18) (19) (20) (21) (22) (23) (24) and fused PBL of Gambian adults immune to Pf malaria with GM4672 cells, a human lymphoblastoid cell line (LCL) (20, 21) . Hybridoma-derived mAb were screened for immune fluorescence reaction with Pf schizonts, for in vitro parasite growth inhibition, and for immune precipitation reaction with the PfMr 195,000 protein.
Materials and Methods
Reagents. Reagents of highest purity available were obtained from the following suppliers: PEG (of 1,500 mol wt), fromJ. T. Baker Chemical Co. Media. The medium used for PWM-stimulation of PBL and for maintenance of the human LCL was RPMI 1640 (Gibco) containing 0.01 Hepes, 0.001 M sodium pyruvate, 0.004 M L-glutamine, four times the concentration of nonessential amino acids, and 11.5% FBS; this medium is referred to as RPMI/Hepes (21) . The hybridoma selection medium is RPMI/Hepes medium containing 10% (vol/vol) NCTC 109 medium, 0.003 M oxaloacetic acid 0.0025 IU/ml insulin, 3.6 x 10 -4 M H, 3.9 X 10 -5 M T, and 3.5 x 10 -7 M A.
Cells. GM 4672 cells containing a small number of EBV DNA copies (based on hybridization with EBV DNA [David Thorley-Lawson, personal communication] ; the cells had previously tested negative for EBV nuclear antigen) were used as fusion partner (18, 21) . For one week every month and one week before fusion, the cells were grown in RPMI/Hepes containing 10 -4 M 6-mercaptopurine.
PBL from three Gambian adults (K. D., K. J., and S. R.), solidly immune of Pf malaria, were isolated from freshly drawn heparinized blood. 4 ml of blood was layered atop 3 ml of Ficoll-Paque and centrifuged at 104 g. After removal of plasma and platelets, the PBL were washed twice in RPMI/Hepes and then cultured in this medium containing PWM (1:1,000 dilution) at a cell density of 106 cells/ml, at 37°C and 5% C02/95% air for 5-7 d.
Fusion. Before fusion, I07 cells of each PWM-stimulated PBL and GM4672 cells were washed twice in serum-free RPMI/Hepes and pelleted together. The cell pellet was overlaid with 0.5 ml of 44% PEG (21), suspended, and pelleted at 300 g for 3 rain. The PEG was diluted by dropwise addition of 10 ml of serum-free RPMI/Hepes over a period of 5 min, and the cells were pelleted again at 500 g for 5 min. The supernatant fluid containing PEG was removed, the cells suspended in RPMI/Hepes maintained at 37°C, 5% CO~/95% air for 24 h, washed, suspended in RPMI/Hepes/HAT, and plated into microtiter plates at a cell density of 2 X l0 p cells/well (19) . The cells were refed twice weekly, and monitored for growth of colonies once a week.
Cloning. Proliferating cells producing antiplasmodial Ig (see below), were first expanded into several macrotiter wells and then cloned twice by limiting dilution into microtiter flat-bottom plates at densities of 30 and 0.3 cells/well. The cells were screened and refed once a week.
Plasmodium Culture. The Gambian K 1 isolate of Pf was maintained in O Rh + eryth-rocytes and serum as in Trager and Jensen (25) , and synchronized weekly using gelatin (26) . Metabolic labeling employed RPMI containing 20% of the normal methionine concentration plus [35S]methionine at a concentration of 0.1 mCi/ml.
Screening for Antiplasmodial Antibodies. The antibody concentration of supernatants was screened using an ELISA, in polystyrene 96-well microtiter plates (Dynatech Laboratories, Inc.; Alexandria, VA). The plates were coated with human IgG or IgM, 2.0 ~g/ml each, solubilized in 0.05 M sodium borate, pH 8.5. The equilibration with culture supernatants and development with alkaline phosphatase-derivatized antibodies and pnitrophenyl phosphate as substrate was as in Schoenfeld et al. (21) . The same ELISA was used to determine the Ig isotype and IgG subclass of mAb. Antiplasmodial antibodies in culture supernatants that tested positive by ELISA were identified using indirect immune fluorescence. Acetone-fixed blood films of Pf cultures (1% hematocrit) at ~10% parasitemia were preincubated with goat serum at a dilution of 1:50, washed, incubated with the hybridoma supernatants for 30 min at 37°C, and washed again. Fluorescein-labeled goat IgG against human IgG and IgM was incubated for 30 min at 37°C. After extensive washing in PBS, the slides were counterstained with Evans Blue and evaluated using a Zeiss epifluorescence microscope.
Supernatants of cloned hybridomas were used to assess the in vitro growth inhibition of Pf by the antiplasmodial antibodies. Gelatin-synchronized Pf cultures (26) were initiated at a parasitemia of-<1% and carried for 72 h in RPMI 1640 medium, refeeding daily as in Trager andJensen (25) . Each supernatant/serum was tested in triplicate. The metabolic labeling was done between 36 and 72 h of the culture, using RPMI 1640 containing 20% of the normal methionine concentration and 0.1 mCi/ml [sSS]methionine. The degree of inhibition was expressed relative to parasite growth obtained with hybridoma supernatants not producing antiplasmodial antibodies and Ig isolated from the sera of the immune PBL donors and of nonimmune individuals (27) .
Immunochemical Techniques. To test for monoclonality of antibodies secreted by hybridomas, we selected only supernatants that, by ELISA, tested positive 10-fold above the background of the GM4672 cells. To metabolically label the IgG/IgM, the hybridomas were incubated during exponential growth in presence of [sSS]methionine, 0.05 mCi/ml, in methionine-free RPMI/Hepes. The Ig was purified on affinity columns using Sepharose 4 B-immobilized goat anti-human Ig. Specifically bound human Ig was eluted with 0.2 M glycine, pH 2.4. The Ig was dialysed against 0.15 M NaCI, concentrated, and subjected to bidimensionai IEF and SDS-PAGE (28) . Heavy and light chains were identified by autoradiography.
[35S]methionine-labeled Pf antigens reacting with human mAb were identified by immune precipitation as previously described (7). Preabsorption of the antigen, the specific immune deposition with mAb, and fractionation of precipitated Pf antigens by SDS-PAGE was also as previously described (7).
Results
Donor Lymphocytes. 30 Hybridomas. 21 -60 d after fusion and maintenance of the fused cells in HAT medium, 29.5, 23.9, and 13.6% of wells of fusions K. J., K. D., and S. R., respectively, contained proliferating hybrid cells producing, by ELISA, IgG and/or IgM 10 times higher than levels found in spent GM4672 culture supernatants (Table I) . This corresponds to a minimum fusion frequency of 6.8 X 10-'~-1.5 X 10 -6. Each fusion yielded equivalent numbers of IgG and IgM at a similar frequency, with a smaller number of wells containing hybridomas producing both IgG and IgM (Table I) . Hybridomas Producing Antiplasmodial Antibodies. Of the 143 Ig-yielding hybridomas, 16 produced IgG/IgM against plasmodial antigens (Table II) , according to immune fluorescence. Positive reactions consisted of diffuse fluorescence of trophozoites and schizonts typical for immune sera (Fig. 1 A) or fluorescence concentrated at the periphery of trophozoites, mature schizonts, and merozoites ( Fig. 1 B) .
Four of seven hybridomas that produced Ig exhibiting significant in vitro inhibition of parasite growth could be cloned at a density of 0.3 cells/microtiter well (Table III) . Preseeding of wells with a feeder layer of peripheral blood mononuclear cells did not increase the cloning efficiency.
Human mAb. Two consecutive affinity adsorptions on Sepharose 4 B-immobilized goat anti-human IgG allowed the purification of human Ig from cell supernatants with good yields. The [35S]methionine-labeled human antibodies of the cloned hybridomas, KJ7-2CllD, KD3-7D3F, KD5-7A8E, and KD8-2B2D, showed only one heavy and light chain each, by IEF/SDS-PAGE, indicating their monocionality. All antibodies inhibited the growth of Pf in vitro (Table III) , reacted strongly with trophozoite/schizont/merozoite surfaces by immune fluorescence (Fig. 1, A and B) , and produced, except for KJ7-2C11D, heavy and light chains different from those of the GM4672 parent line (Table III) .
Inhibition of Pf Growth In Vitro by Human mAb. Inhibition of growth was assessed by [35S]
methionine metabolically incorporated by synchronized Pf cultures over a period of 36 h during schizont maturation and merozoite reinvasion; only inhibition of 45% or more was significant, applying the double-blind t test. 'y~/K 0.02 * Based on ELISA; cell density of 106 cells/ml. * At Ig concentration of 1 t~g/ml. Tested using the Gambian K1 strain.
§ GM4672 is the human lymphoblastoid cell line used as fusion partner.
A l t h o u g h g r o w t h inhibition o f h u m a n m A b was normalized to 1 ~g I g per rnil|iliter o f m e d i u m (Table III) (Fig. 2, lane 4) . Discussion Our results show that one can produce human mAb to Pf antigens using hybridomas from human LCL and PBL of individuals immune to Pf malaria, and obtain a high yield of Ig-producing hybridomas relative to previously reported (21) experiences with the GM4672 line. The high frequency of IgGsecreting hybrid cells may be due to (a) stimulation of the PBL for 6-7 d, at which time predominantly IgG-producing lymphocytes elicit a proliferative response (29) , and (b) increased susceptibility to mitogen stimulation and/or fusion with human LCL of PBL from individuals chronically exposed to malaria and other infections.
Since the experiments in man testing the protective capacity of immune lgG from individuals immune to Pf malaria (30) , much research has been devoted to the humoral immune response to the malarial parasite and the identification of potentially protective Plasmodium blood stage antigens. Although polyspecific immune sera have allowed the identification of certain candidate antigens (13, 16, 31) , no unambiguous correlation between protection and antibodies to a defined antigen has been found to date (13, 14) .
The complexity of the immune response to Plasmodium antigens may be due to the fact that a given antigen may contain epitopes of very different immunogenicity. Evidence for this is available from gene cloning and DNA-sequencing experiments that provided the amino acid sequences of certain Plasmodium proteins. These proteins contain repetitive amino acid sequences (32, 33) that are highly immunogenic, but antibodies against them do not necessarily provide antiplasmodial activity (34, 35) . In fact, the function of these peptides may be to divert the hosts' immune response. At least one category of antigens bearing repetitive amino acid sequences, the circumsporozoite (CS) antigen, contains, in addition to the tandem repeat amino acid sequences (36) , portions that are conserved throughout different Plasmodium species (37, 38 16) relative to some murine mAb against the analogous M~ 230,000 protein of Pk (15) suggests that short term immunization with incompatible Plasmodiura parasites does not necessarily lead to the production of antibodies with similar epitope specificities as of those antibodies produced by the natural host after exposure to malaria over a long time.
The biological activity of our human mAb and of IgG to the Pf Mr 195,000 protein in one other study (16) , together with the demonstration that this category of proteins is protective in three host-parasite systems (7, 10, 17) makes the Mr 195,000 component a potential candidate antigen for use as a vaccine against Pf malaria. One can expect that human mAb against this protein will become valuable in three respects: (a) the identification, characterization, and isolation of antigenic peptides of high-Mr schizont/merozoite antigens of human Plasmodium, (b) identification of portions of the Pf genome encoding these peptides, and (c) their use as therapeutic reagents for severe cases of drugresistant malaria.
Summary
Using the human lymphoblastoid cell line, GM 4672, and PBL of Gambian adults immune to Plasmodiumfalciparum (PI) malaria, we have produced humanhuman hybridomas and selected those that produce mAb against Pf antigens.
The fusion frequency, using PWM-stimulated donor lymphocytes was between 6.8 × 10 -5 and 1.5 × 10 -6. Using immune fluorescence, immune precipitation, and Pf in vitro growth inhibition, we cloned four hybridomas that reacted with the Pf Mr 195,000 schizont/merozoite protein. The differences in proteins immune precipitated and in growth inhibition indicate that, during development of protective immunity against Pf malaria, a spectrum of antibodies is produced reacting with different epitopes on the same antigen. Only a portion of these antibodies exhibits biological activity, suggesting that the recognition of certain epitopes is required for the development of a protective immune response.
